8-K: Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Lung Cancer Trial Amidst Executive Changes

Genprex has dosed the first patient in the Phase 2a expansion of its Acclaim-1 clinical trial for lung cancer, while also announcing the departure of a key executive and providing an update on the CEO's health.

Summary

• Genprex has initiated the Phase 2a expansion of its Acclaim-1 clinical trial, dosing the first patient in January 2024.
• The Acclaim-1 study is evaluating Reqorsa Therapy in combination with Tagrisso for patients with advanced Non-Small Cell Lung Cancer (NSCLC) who have progressed after Tagrisso treatment.
• The Phase 2a expansion will enroll 19 patients per cohort and is expected to be completed by the end of 2024, with an interim analysis anticipated in 2025.
• Data from the Phase 1 dose escalation portion of the trial showed promising efficacy, with some patients experiencing partial remission or stable disease for extended periods.
• Catherine Vaczy, the Executive Vice President, General Counsel, and Chief Strategy Officer, has left the company on February 4, 2024.
• CEO Rodney Varner continues in his role while undergoing treatment for cutaneous lymphoma, with CFO Ryan Confer designated to cover his responsibilities when he is unavailable.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in the clinical trial, but tempered by the executive departure and the CEO's health issues. The forward-looking statements also highlight risks and uncertainties.

Positives

• The initiation of the Phase 2a expansion of the Acclaim-1 trial is a positive step in the clinical development of Reqorsa Therapy.
• The Phase 1 data showed promising efficacy results, with some patients experiencing partial remission or stable disease for extended periods.
• The extended progression free survival (PFS) observed in some patients is consistent with prior early stage clinical trials of REQORSA.
• The company has a plan for business continuity with the CFO covering for the CEO when needed.

Negatives

• The departure of Catherine Vaczy, a key executive, could create some disruption.
• The CEO's ongoing health issues and limitations on business activities and travel could impact the company's operations.

Risks

• The company's forward-looking statements are subject to significant risks and uncertainties, including the success of clinical trials and regulatory approvals.
• There is a risk that the company may not be able to maintain compliance with Nasdaq listing requirements or obtain sufficient capital.
• The company's reliance on third-party vendors, suppliers, and manufacturers poses a risk to the successful production of its product candidates.
• The company's intellectual property and licenses are subject to risks.

Future Outlook

Genprex expects to complete the enrollment of 19 patients in each cohort of the Phase 2a expansion portion of the Acclaim-1 study by the end of 2024 and anticipates an interim analysis in 2025. The company also acknowledges the risks and uncertainties associated with forward-looking statements.

Management Comments

• The company believes promising efficacy results were observed in the Phase 1 portion of the Acclaim-1 study.
• The extended progression free survival (PFS) of some patients is consistent with long-term PFS seen in prior early stage clinical trials of REQORSA.
• The company is in discussions with Ms. Vaczy regarding her departure.

Industry Context

The announcement of the first patient dosed in the Phase 2a expansion of the Acclaim-1 trial is a positive development for Genprex in the competitive landscape of cancer therapeutics. The trial targets a specific subset of NSCLC patients with EGFR mutations, a common target in lung cancer research. The combination therapy approach with Tagrisso is also a common strategy in the field.

Comparison to Industry Standards

• The Acclaim-1 trial's focus on EGFR-mutated NSCLC is consistent with industry trends, as this is a well-established target for lung cancer therapies.
• The use of Tagrisso as a combination therapy is also in line with current treatment strategies for this patient population.
• The reported progression-free survival (PFS) in the Phase 1 trial is comparable to results seen in other early-stage trials of similar therapies, but more data is needed from the Phase 2a expansion to make a definitive comparison.
• Companies like AstraZeneca, the maker of Tagrisso, are key competitors in this space, and Genprex's success will depend on demonstrating superior efficacy and safety with its combination therapy.

Management Changes

Stakeholder Impact

• Shareholders may react positively to the clinical trial progress but negatively to the executive departure and CEO's health issues.
• Employees may experience some uncertainty due to the executive change.
• Patients with NSCLC may benefit from the potential of Reqorsa Therapy.
• The company's suppliers and vendors may be impacted by the company's financial status and ability to scale up production.

Next Steps

• Genprex will continue to enroll patients in the Phase 2a expansion of the Acclaim-1 study.
• The company will conduct an interim analysis of the Phase 2a expansion data in 2025.
• Genprex will continue discussions with Ms. Vaczy regarding her departure.

Key Dates

Keywords

Genprex, Reqorsa Therapy, Acclaim-1, Non-Small Cell Lung Cancer, NSCLC, Tagrisso, Clinical Trial, Phase 2a, Cancer Therapeutics, Executive Departure